Transgenic animals were developed to assess the role of insulin-like growth factor 1 (IGF-1) in skin growth, dierentiation and organization, as well as its importance in tumor formation. Expression of a human IGF-1 cDNA was targeted to the interfollicular epidermis of transgenic mice using a human keratin 1 promoter construct (HK1). Transgenic animals (HK1.IGF-1 mice) could be identi®ed at birth by early ear unfolding and excessive ear and skin growth compared to nontransgenic littermates. Further examination of the skin from these mice showed epidermal hyperplasia and hyperkeratosis, marked thickening of the dermis and hypodermis, and early hair follicle generation in newborns. The severity of this phenotype correlated with transgene expression both of which subsided with age. Adult HK1.IGF-1 mice developed spontaneous tumors following treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) alone and exhibited an exaggerated epidermal proliferative response following treatment with the tumor promoter compared to non transgenic littermates. Additionally, HK1.IGF-1 transgenic mice developed papillomas faster and in markedly greater numbers compared to non-transgenic littermates in standard initiation-promotion experiments. The data presented suggest an important role for IGF-1 in the process of multistage carcinogenesis in mouse skin.
Introduction
The insulin-like growth factors (IGFs) play important roles in several biological processes including growth, embryogenesis, and carcinogenesis (for review see Baker et al., 1993 and Baserga, 1995) , and have pleiotropic eects on a number of organs at various stages of mammalian development. IGF-1 is expressed primarily in the liver, and circulates in an endocrinelike fashion with the assistance of binding proteins (Froesch et al., 1985; Shimasaki and Ling, 1991; Rechler and Brown, 1992) . However, extrahepatic expression of the IGF-1 gene also occurs in a cell speci®c manner, where the action of the growth factor is paracrine. In human skin, for example, IGF-1 produced by dermal ®broblasts activates the IGF-1 receptor on keratinocytes in the epidermis (Tavakkol et al., 1992; Ando and Jensen, 1993) . Both localized and systemic expression of IGF-1 are regulated, in part, by growth hormone (GH), as well as other growth factors, and IGF-1 expression changes as a result of developmental and nutritional signals (Rotwein et al., 1993) .
The numerous functions of IGF-1 in development and growth are exempli®ed by the multitude of signals transduced as a result of the binding of IGF-1 to IGF1r. IGF-1r activation can result in metabolic changes stimulated by phosphatidylinositol 3-kinase as indicated by the uptake of glucose, and mitogenic changes induced by signaling through pathways mediated by protooncogenes such as ras or src (Czech, 1989; Takahashi et al., 1995; Kozma and Weber, 1990) . Also, signal transduction mediated by receptor tyrosine kinases other than IGF-1r may be dependent on the activation of a subset of downstream factors by IGF1r. For example, epidermal growth factor receptor (EGFr) overexpression will confer ligand-dependent transformation to ®broblasts only in the presence of a functional IGF-1r . Additional studies suggest that keratinocytes require IGF-1 to induce other growth factors such as ligands for the EGFr (Vardy et al., 1995) .
Evidence for the involvement of IGF-1 signaling in tumorigenesis comes from several distinct observations as follows: (i) tumors originating from breast (Yee et al., 1989) , colon (Tricoli et al., 1986) , and lung (Minuto et al., 1986) in humans, and skin in mouse (Rho et al., 1996) have been shown to overexpress either IGF-1, IGF-1r or both; (ii) overexpression of IGF-1r confers ligand dependent transformation in cultured cells (Kaleko et al., 1990) ; (iii) IGF-1 expression is elevated in cells carrying an activated p21
Ha-ras (Dawson et al., 1995) ; (iv) IGF-1 has been shown to induce the expression of other mitogenic growth factors (Vardy et al., 1995) ; and (v) ®broblasts obtained from IGF-1r null mice were highly resistant to transformation by SV40-T antigen, activated Ha-ras, or a combination of both, while re-introduction of wild-type IGF-1r again conferred susceptibility to transformation (Sell et al., 1993 and Sell et al., 1994) .
Collectively, the above data support the importance of developing in vivo model systems in which to study the importance of IGF-1 overexpression in tumorigenesis. While transgenic mice overexpressing IGF-1 have been created (Quaife et al., 1989 and Matthews et al., 1988) , studies in these animals were not designed to establish a link between carcinogenesis and IGF-1 signaling. To this extent, we have chosen the mouse skin model in which to evaluate the impact of IGF-1 on tumorigenesis by expressing IGF-1 in the epidermis of transgenic mice using a human keratin 1 promoter (HK1) (Rothnagel et al., 1990) . The HK1 vector targets expression primarily to the suprabasal compartment with some expression in the basal compartment of the interfollicular epidermis Rosethal et al., 1991) . In addition, expression driven by this promoter occurs late in gestation such that expression of the transgene has little impact on prenatal growth and development. In the current paper, we describe the neonatal characteristics that occur as a result of IGF-1 overexpression in mouse epidermis, as well as the impact of IGF-1 on tumorigenesis in this tissue. The results indicate that IGF-1 overexpression can substitute for Ha-ras activation similar to overexpression of TGFa (Dominey et al., 1993; Greenhalgh et al., 1993; Vassar and Fuchs, 1991) . In addition, IGF-1 overexpression dramatically potentiates the epidermal proliferative response and the skin tumor promoting activity of the potent phorbol ester tumor promoter, 12-Otetradecanoylphorbol-13-acetate (TPA). These results demonstrate for the ®rst time that IGF-1 dramatically in¯uences epithelial tumorigenesis in vivo.
Results

Generation of HK1.IGF-1 transgenic mice
To target expression of IGF-1 to the epidermis of transgenic mice, a construct was made by inserting the human IGF-1 cDNA into the human keratin 1 expression vector pHK1 as shown in Figure 1a . This vector utilizes human keratin 1 gene intron sequences as well as polyadenylation signals to direct optimal expression of the inserted cDNA speci®cally to the interfollicular epidermis of the skin (Rothnagel et al., 1990 and Greenhalgh et al., 1994) . A 7.2 kb EcoRI HK1.IGF-1 recombinant fragment was puri®ed and injected into one-cell embryos from FVB6ICR F 1 mice. Four founders were determined to carry the transgene by PCR analysis of tail DNA. Three of these mice passed the transgene in Mendelian fashion to their ospring, and presented morphological dierences that distinguished them from non-transgenic animals. The diminished phenotype of one line, HI.8, suggested that expression of the transgene was reduced in comparison to the other two lines, since phenotypic characteristics of IGF-1 overexpression were apparent but not as striking as the other two lines. The gross physical characteristics of newborn ospring from each of two remaining lines were similar, as was the appearance of skin at the microscopic level (see below). Viable homozygote transgenic animals have been generated from each of these lines, suggesting that neither transgene insertion event disrupted an essential gene. Of the founders for these two transgenic lines, founder HI.7 produced few ospring and was incompatible with female mice, therefore, experiments were performed using the ospring from founder HI.5.
Physical characteristics resulting from HK1.IGF-1 transgene expression
To con®rm expression from the HK1.IGF-1 transgene, reverse transcription followed by polymerase chain reaction (RT ± PCR) was performed on total RNA isolated from the skin of transgenic mice and nontransgenic littermates. Human IGF-1 mRNA was detected in total RNA isolated from the skin of 3 and 5 day old progeny obtained from founders HI.5 and HI.7 (Figure 1b) . The speci®city of the oligonucleotides was con®rmed by the lack of an RT ± PCR product in RNA samples from non-transgenic littermates. The absence of contaminating genomic DNA in the RNA samples was indicated by the lack of PCR product when no reverse transcriptase was used in the reaction (data not shown). The presence of the transgene in genomic DNA and expression of IGF-1 mRNA correlated with obvious physical characteristics in newborns. Speci®cally, at birth the ears of transgenic animals were prematurely unfolded and signi®cantly larger than ears on non-transgenic littermates. By 2 to 3 days of age the skin of HK1.IGF-1 transgenic mice was obviously thicker and more wrinkled than that of the controls. For example, milk in the stomach of transgenic animals was barely visible, whereas milk in the stomachs of non-transgenics was easily seen. At 5 days of age the skin of transgenic animals remained noticeably thickened and wrinkled compared to control littermates. In addition, hair growth was already apparent in transgenic mice but not in non-transgenic littermates at this time. Closer examination of the hair in these animals showed long thin shafts of hair projecting from the skin 2 to 3 days in advance of the emergence of hair in siblings not carrying the transgene. When mature, the larger ears of transgenic animals easily distinguished them from non-transgenic littermates and eliminated the need for genotyping.
Histological evaluation of skin from HK1.IGF-1 transgenic mice Histologic evaluation of skin from transgenic mice showed signi®cant alterations compared to non-transgenic littermates (Figure 2 ). There was marked epidermal hyperplasia and hyperkeratosis of the stratum corneum in 5 day old HK1.IGF-1 mice (Figure 2b ) compared to non-transgenic littermates (Figure 2a ). These epidermal changes were associated with elevated epidermal labeling index (LI) in transgenic vs non-transgenic mice (19.3% vs 11.6%, respectively) ( Figures 2f and e, respectively) . Furthermore, labeled nuclei in some sections were observed in the stratum spinosum indicating that overexpression of IGF-1 led to expansion of the proliferative compartment into this epidermal layer. In addition to the epidermal changes noted above, skins from transgenic mice also exhibited signi®cant alterations in the dermis and hypodermis. In particular, the dermis of skin from HK1.IGF-1 mice was signi®cantly thicker than the dermis of skin from non-transgenic mice (compare Figures 2d and c, respectively). Further analysis revealed that the hypodermis was also thicker in transgenic vs nontransgenic skin. The hair follicles also appeared more disorganized in the skin of transgenic mice. In some sections it appeared that there were many more hair follicles in transgenic than non-transgenic mice, an observation more readily seen in sections of lower magni®cation such as those shown in Figures 2d and c , respectively. This observation may be more apparent than real and may be the result of elongated hair shafts present in the skin of transgenic mice.
Skin sections from transgenic mice and nontransgenic littermates were also analysed for the expression of keratins 1, 6, 13 and 14 (data not .5 a Groups of three mice each were treated with TPA or acetone four times over 2 weeks and killed 24 h after the last treatment. BrdU (in PBS) was injected i.p. (100 mg/gram body weight) 30 min prior to sacri®ce. Epidermal thickness and LI were determined as previously described (Naito et al., 1987) . Values in the Table represent means+SEM. The dierences in epidermal thickness values and LI between transgenic and control samples for a given dose of TPA were found to be statistically signi®cant (P<0.001) by the Mann Whitney U test 
Immuno¯uorescence localization of transgene expression
The localization of transgene expression in skin of transgenic mice was determined by immunofluorescence (Figure 2 ). Human IGF-1 protein was expressed primarily in the suprabasal layer in HK1.IGF-1 mice with some expression also evident in the basal layer of the epidermis (Figure 2h ). The human IGF-1 antibody used in these experiments did not detect endogenous murine IGF-1 as evidenced by the lack of immunouorescence in skin sections of non-transgenic mice (Figure 2g) . Notably, expression of the transgene, as detected by immuno¯uorescence, subsided in older mice and was undetectable using this methodology by 21 days of age. However, IGF-1 mRNA was detectable in 21 day old as well as older HK1.IGF-1 mice by RT ± PCR. Accordingly, both the epidermal and dermal changes observed in 5 day old transgenic mice also subsided with age (data not shown). Thus, transgene expression clearly correlated with the severity of the phenotype.
Analysis of TPA responsiveness in HK1.IGF-1 transgenic mice HK1.IGF-1 transgenic mice were analysed for their responsiveness to the phorbol ester skin tumor promoter, TPA. Epidermal hyperplasia (measured as epidermal thickness) and epidermal LI were assessed in HK1.IGF-1 mice following topical treatment with either 1.7 or 6.8 nmol TPA or 0.2 ml of the acetone vehicle. For these experiments, adult mice received four applications of the promoter or vehicle, given twiceweekly, and then were sacri®ced at several time points after the last treatment. The results of these experiments are shown in Figure 3 and Table 1. IGF-1 expression in the epidermis of transgenic mice produced a dramatic hypersensitivity to the eects of TPA. As shown in Figure 3b (and summarized in Table 1 ), 6.8 nmol TPA induced a signi®cantly greater epidermal hyperplasia in adult HK1.IGF-1 mice 24 h after the last treatment compared to age-matched nontransgenic littermates (Figure 3a) . The dierence in magnitude of the LI (a direct measure of epidermal proliferation) was particularly striking (compare panels d and c for HK1.IGF-1 and non-transgenic mice, respectively). Similar results were obtained with 1.7 nmol TPA (also summarized in Table 1 ). Notably, transgene expression was again detectable by immuno¯uorescence in hyperplastic epidermis 24 h after the last TPA treatment as shown in Figure 3f . Furthermore, transgene expression in hyperplastic skin induced by TPA treatment was predominantly in the suprabasal layers.
Spontaneous and induced tumor formation in HK1.IGF-1 transgenic mice
To further characterize the eect of targeted expression of IGF-1 in mouse epidermis, HK1.IGF-1 mice were examined for both spontaneous and induced tumorigenesis. To date, no skin tumors have been detected on untreated founders or F 1 mice out to age 13 months. However, 60% of the transgenic mice that received only TPA (10 nmol) treatment developed skin papillomas by 20 weeks of promotion (an average of 1.1 papilloma per mouse). In contrast, no tumors were present on the skin of non-transgenic littermates treated only with TPA for 20 weeks. These results are shown in Figure 4 . TPA treated HK1-IGF-1 mice also had tumors outside the area of TPA application (e.g. near the genitals). In addition to these groups of mice, groups of HK1.IGF-1 transgenic mice and agematched, non-transgenic control mice were initiated with 25 nmol of DMBA. Four weeks later, each group received treatments with 10 nmol of TPA twice weekly. By 3 weeks of promotion papillomas were visible on the skin of initiated HK1.IGF-1 mice, and by 4 weeks .IGF-1 mice that received the acetone vehicle (0.2 ml) at initiation followed by promotion with 10 nmol TPA; and (*), non-transgenic mice that received the acetone vehicle (0.2 ml) at initiation followed by promotion with 10 nmol TPA IGF-1 in multistage carcinogenesis DK Bol et al of TPA treatment 100% of these mice exhibited tumors. In contrast, none of the non-transgenic animals had papillomas at this time point (Figure 4) .
Tumors arose and grew very rapidly in transgenic animals. For example, at 7 weeks of promotion, initiated control mice had an average of one tumor per mouse, and HK1.IGF-1 mice had an average tumor burden of 33 papillomas. Surprisingly, many of these tumors were already approaching 1 cm in diameter. The papilloma response reached a plateau by 18 weeks in both transgenic and non-transgenic mice that had been initiated with DMBA and promoted with TPA. The maximum number of papillomas per mouse was 51.5 and 11.8 for transgenic and non-transgenic mice, respectively. Histologically, the papillomas induced on transgenic mice either by TPA alone or following initiation with DMBA and promotion with TPA were similar in appearance to those induced on non-transgenic mice following DMBA-TPA (see Figures 5a and b) . These tumors were characterized grossly as exophytic lesions. Histologically, these tumors were well dierentiated, hyperplastic lesions with few atypical cells in the basal layer and numerous areas of horny material. Analysis of transgene expression in skin papillomas by immuno¯uorescence showed that most of the epithelial component of these tumors had intense staining for the human IGF-1 protein (Figure 5c ).
Discussion
The expression of IGF-1 was successfully targeted to the epidermis of transgenic mice using the HK1 expression vector. Three transgenic lines were established that passed the transgene and phenotype to progeny, the severity of which varied between one line compared to the other two. Overexpression of IGF-1 in the epidermis of these mice resulted in characteristics that were immediately obvious at birth. Aected mice had thick wrinkled skin and large ears in addition to hyperkeratosis and atypical epidermal hyperplasia for young animals. The thick skin characteristics of these mice persisted in newborns and was more obvious at the time of hair emergence, which was approximately 2 days earlier in transgenic than in control animals. Expression of human IGF-1 in adult mice potentiated the response of transgenic animals to proliferation induced by the tumor promoter, TPA. Moreover, tumors arose spontaneously in transgenic mice without the need for tumor initiation with a DNA damaging agent. In addition, transgenic mice exposed to an initiation-promotion protocol using DMBA-TPA developed tumors considerably faster and in far greater numbers than similarly treated non-transgenic mice.
Collectively, these data demonstrate for the ®rst time that signaling through the IGF-1r plays an important role in the development of skin tumors in an in vivo model of epithelial tumorigenesis.
Signaling through the IGF-1 receptor has been shown to be essential for the development and growth of the skin, as mice lacking the IGF-1r have hypoplastic skin . While transgenic animals overexpressing IGF-1 (driven by a metalothionein promoter) have been described previously (Matthews et al., 1988) , a signi®cant skin phenotype was not reported in these animals. Two additional studies have described the results of transgenic overexpression of IGF-2 (Ward et al., 1994 and Rogler et al., 1994) , another IGF-1r ligand. In one of these studies, IGF-2 expression was driven in transgenic mice by the major urinary protein promoter (Rogler et al., 1994) . While these mice developed hypoglycemia and hypoinsulinemia, as well as a variety of tumors in older animals, a signi®cant skin phenotype was not reported. In the second study, overexpression of IGF-2 in only the suprabasal layer of epidermis using a bovine K10 promoter resulted in overgrowth of the skin and mild hyperplasia and hyperkeratosis (Ward et al., 1994) . These latter results, in combination with the results reported in our current study, suggest that overexpression of an IGF-1r ligand in the suprabasal compartment of the epidermis results in excessive (Ward et al., 1994) . Importantly, however, expression of IGF-1 in the basal layer in addition to the suprabasal layer, as seen in the skin of HK1.IGF-1 mice generated in our current study (Figure 2 ), had a more dramatic impact on epidermal proliferation and dierentiation than observed in mice overexpressing IGF-2 in only the suprabasal compartment. Finally, the dramatic changes in the dermis and hypodermis were unique to the HK1.IGF-1 mice (see again Figure 2 ) and not present in any of the other IGF-1 and IGF-2 transgenic mice reported to date. Thus, it is likely that the speci®c compartment within the epidermis in which this growth factor is expressed in¯uences the phenotype observed.
In fact, we have recently targeted expression of IGF-1 exclusively to the basal layer of the interfollicular epidermis and hair follicles using a bovine K5 promoter. Preliminary analysis of founders showed both epidermal hyperplasia and a very dramatic hyperkeratosis, in addition to marked dermal changes (D Bol, J Jorcano, and J DiGiovanni, unpublished observations). The HK1.IGF-1 mice generated in our current study share both similarities as well as dierences compared to several transgenic mice generated with the same HK1 vector. In particular, HK1.TGFa mice displayed excessive epidermal hyperplasia and scaly, hyperkeratotic skin at birth. In addition, HK1.TGFa mice exhibited precocious eyelid opening, as well as, retarded hair growth early in life (Dominey et al., 1993) . Another transgenic mouse overexpressing TGFa from a basal (K14) keratinocyte promoter showed similar characteristics (Vassar and Fuchs, 1991) . In contrast, HK1.IGF-1 mice had more pronounced hair growth and dermal abnormalities not seen in HK1.TGFa transgenics, in addition to epidermal hyperplasia and hyperkeratosis. HK1.TGFa mice developed squamous papillomas following exposure to a promotion stimulus, but in the absence of exposure to an initiating agent. It was hypothesized that constitutive signaling through the EGFr and activation of the Ha-ras signal transduction cascade could subsitute for Ha-ras activation that occurs as a result of carcinogen DNA adduct formation and subsequent mutation during the process of tumor initiation (Jhappan et al., 1994; Wang et al., 1994; Vassar et al., 1992) . Our results demonstrated that HK1.IGF-1 mice also developed skin papillomas following exposure to the tumor promoter TPA. That tumors developed in the HK1.IGF-1 transgenic mice in the absence of exposure to an initiating carcinogen also suggests that IGF-1 overexpression can substitute for an initiating event possibly by a similar mechanism.
In comparison to HK1.ras transgenic mice (Greenhalgh et al., 1993), HK1.IGF-1 mice exhibited a less severe hyperplasia and hyperkeratosis, however, the hair follicle and dermal abnormalities were again speci®c to the HK1.IGF-1 transgenic mice. In addition, tumors appeared in HK1.ras mice especially at sites of wounding similar to that observed in HK1.TGFa mice. Therefore, the HK1.TGFa, HK1.ras, and HK1.IGF-1 phenotypes were similar in terms of spontaneous tumor development except that HK1.IGF-1 mice did not develop tumors in the absence of TPA. This latter observation may be due to the fact that the epidermal hyperplasia was less severe in HK1.IGF-1 mice compared to HK1.TGFa and HK1.ras possibly indicating the need for a stronger promoting stimulus for tumor development. The HK1.ras phenotype may be due, in part, to overproduction of growth factors. In this regard, overexpression of Ha-ras has been linked to upregulation of TGFa and other EGFr ligands (Dlugosz et al., 1995) . It is also interesting to note that, in some epithelial tumors, it is thought that IGF-1 overexpression is a result of, and potential means for proliferation induced by activated Ha-ras. (Dawson et al., 1995) . Notably, embryonic ®broblasts from IGF-1r 7/7 knockout mice are resistant to transformation by ras overexpression . Thus, transgenic overexpression of IGF-1 may, in part, mimic conditions under which activated Ha-ras drives transformation by the induction of this growth factor. Alternatively, overexpression of IGF-1 may exert an indirect eect on the epidermis by inducing other growth factors in this issue (Vardy et al., 1995) . Future experiments crossing HK1.TGFa and HK1.ras transgenic mice with HK1.IGF-1 transgenics will help determine the overlap between signaling pathways induced by IGF-1 and TGFa, and their coordinate eect on tumor growth.
In addition to developing spontaneous tumors, HK1.IGF mice treated with DMBA prior to multiple TPA treatments in a standard initiation-promotion tumorigenesis protocol had greater numbers of tumors compared to control animals ( Figure 4 ). Tumors also developed at a very rapid rate in HK1.IGF-1 transgenic mice compared to non-transgenic littermates. This dramatic increase in tumor formation in HK1.IGF-1 transgenic mice may be explained, in part, by their enhanced sensitivity to the tumor promoter, TPA. In this regard, HK1.IGF-1 mice also showed enhanced sensitivity to TPA treatment that resulted in a fourfold greater epidermal LI compared to nontransgenic control animals. That HK1.IGF-1 mice also had fourfold more tumors than control animals treated with the same doses of DMBA and TPA suggests that IGF-1-mediated sensitivity to TPA was, at least, partly responsible for the greater tumor response in the HK1.IGF-1 transgenics. One possible mechanism for the enhanced sensitivity of HK1.IGF-1 mice to the proliferative eects of TPA may be due to enhanced cooperativity between the IGF-1r and EGFr signaling pathways. In particular, previous studies from our laboratory have shown that levels of TGFa and other EGFr ligands rise dramatically in response to TPA treatment resulting in activation of the EGFr during tumor promotion Xian et al., 1995) . In HK1.IGF-1 transgenic mice, high levels of IGF-1 may cause greater proliferation in response to TPA treatment, by cooperation between the IGF-1r and EGFr signaling pathways. However, it was somewhat surprising that HK1.IGF-1 transgenic mice developed an average of more than 50 papillomas per mouse with the doses of DMBA and TPA used in the tumor experiment. Even SENCAR mice, which are highly sensitive to TPA, do not develop this many tumors at the same doses of DMBA and TPA (Ewing et al., 1988) . Therefore, the dramatic increase in tumor number in HK1.IGF-1 transgenic mice raises the possibility that overexpression of this growth factor in skin may have in¯uenced the initiation stage or alternatively may have led to the recruitment of a population of initiated cells not normally promoted by TPA. Recent studies have shown that signaling through the IGF-1r blocks apoptosis, a mechanism whereby damaged cells may be removed from a tissue (Resnico et al., 1995) . Perhaps some initiated cells that would otherwise die are now able to survive as a result of transgene expression and grow into tumors in HK1.IGF-1 mice. Future studies will explore these possibilities.
In conclusion, the use of targeting vectors to determine the role of growth factors and their receptors in the development of cancer has become an important means of studying the in vivo potential of these molecules in animal model systems. The creation of a transgenic mouse where IGF-1 expression was targeted to the epidermis has allowed us to show, for the ®rst time, an important role for this growth factor in the development of epithelial tumors in an in vivo model of chemical carcinogenesis. The availability of these animals will allow us to test a number of important hypotheses regarding the potential interaction of the IGF-1r signaling pathway with other signaling pathways, including the EGFr pathway, during mitogenesis and tumorigenesis. In addition, the extreme sensitivity of HK1.IGF-1 mice to tumor promotion with the phorbol ester, TPA, suggests that these mice may also be highly sensitive to other tumor promoters. Further study will reveal whether these mice might be useful as a short-term bioassay for potential tumor promoters and/or nongenotoxic carcinogens. Finally, these mice may be useful in dissecting the role of the Ha-ras signaling pathway during both the tumor initiation and promotion stages of multistage epithelial tumorgenesis.
Materials and methods
DNA construction
The DNA construct used for generating transgenic mice is shown in Figure 1a . The human IGF-1 cDNA was excised from the parent vector pGEM (a gift from Dr KH Gabbay, Baylor College of Medicine) (Jansen et al., 1983) , with restriction enzymes EcoRI and BamHI. The termini of this fragment, containing the B-, C-, and A-chains of IGF-1, were ®lled in with the Klenow form of DNA polymerase and the blunt-ended fragment was ligated into the SmaI restriction enzyme site of the keratinocyte expression vector pHK1 (a gift from Dr Dennis Roop, Baylor College of Medicine) (Rothnagel et al., 1990) . Orientation and integrity of the cDNA insert was determined by sequencing the human IGF-1 cDNA within the HK1 construct. The resulting construct, pHK1.IGF-1, contained the human keratin 1 promoter for transcription through the ®rst intron of the HK1 gene, the hIGF-1 cDNA, and the HK1 polyadenylation signal.
Preparation of DNA for microinjection
Plasmid DNA was prepared by standard techniques (Sambrook et al., 1989) . pHK1.IGF-1 was digested with EcoRI to release the vector sequences from the expression construct, and the two fragments separated by electrophoresis through a 0.8% agarose gel. The larger fragment containing the expression construct was isolated from a gel slice by electrophoresis into a dialysis bag, and the DNA puri®ed using the Prepagene DNA cleanup kit according to manufacturers recommendations (BioRad). DNA was eluted from the puri®cation resin with 10 mM Tris-HCl (pH 7.6), 0.1 mM EDTA, and quantitated. For injection, the DNA was diluted to 5 ng/ml in the elution buer and spun repeatedly to remove carryover resin.
Generation and identi®cation of transgenic mice
Donor embryos for injection were generated through a mating of FVB (National Cancer Research Facility, Frederick, Maryland) male to superovulated ICR (Harlan Sprague Dawley) female mice, and were isolated as described (Hogan et al., 1986) . DNA was injected into the pronucleus of these F 1 embryos, and survivors were transferred to pseudopregnant ICR females. Transgenic animals were identi®ed by PCR on the DNA from the tails of weanlings (Miller et al., 1988) . Oligonucleotides speci®c for the human IGF-1 cDNA were 5'TGCCACGGCTGGACCGGAGACG3' (upstream) and 5' GCA TGT CAC TCT TCA CT CCTC 3' (downstream), which yielded a 361 bp fragment in a PCR reaction using the human IGF-1 cDNA as a template. After con®rming the presence of the HK1.IGF-1 transgene, and associating transgene expression with a phenotype, transgenic and non-transgenic animals were distinguished by physical characteristics and not by genotype.
Preparation and analysis of RNA
Total RNA was isolated from the skin of mice by methods described previously (Chomczynski and Sacchi, 1987) . Brie¯y, whole skin from either transgenic or control animals was frozen in liquid nitrogen. Pieces of skin were then pulverized with a mortar and pestle and the cells lysed in guanidinium isothiocyanate solution. RNA was then puri®ed by extraction with water-saturated phenol followed by precipitation with isopropanol. To reduce background ampli®cation from transgene copies in the genome, RNA samples were treated with RNase-free DNase prior to further manipulation.
Transgene expression was determined by RT ± PCR (Figure 1b ) using the prepared RNA as an initial substrate. cDNA was generated by incubation of random hexamers and 2 mg of total RNA in the presence of reverse transcriptase according to manufacturer's instructions (BRL, Bethesda, Maryland) . Expression of the human IGF-1 transgene was then detected by using an aliquot of this reaction in a PCR reaction with the human IGF-1 speci®c oligonucleotides described above.
Histological analyses
Dorsal skin samples and tumors were ®xed in formalin and embedded in paran prior to sectioning. Sections of 4 mm were cut and stained with hematoxylin-eosin (H&E). Mice were injected i.p. with bromodeoxyuridine (BrdU) in PBS (100 mg/gm body weight) 30 min prior to sacri®ce. For the analysis of epidermal labeling index (LI), paran sections were stained using anti-BrdU antibody as previously described (Eldridge et al., 1990) .
For the analysis of TPA eects, adult female HK1.IGF-1 mice or non-transgenic littermates (7 ± 9 weeks old) were shaved on the dorsal side and 2 days later treated topically with 1.7 or 6.8 nmol TPA or the acetone vehicle (0.2 ml). Treatment with TPA or the acetone vehicle was given twiceweekly over a 2 week period (four doses total) and then mice were sacri®ced at various times after the last treatment. Thirty minutes prior to sacri®ce mice received i.p. injections of BrdU as described above. The dorsal skin was removed, ®xed in formalin and embedded in paran and then subsequently processed for conventional H&E staining and BrdU labeling as described above. The determinations of epidermal thickness and LI were performed as previously described (Naito et al., 1987) .
Immunohistochemical staining for keratins
Immunohistochemical analysis for epidermal keratins was carried out in paran sections mounted on poly-L-lysine coated slides. K1, K14, K6 and K13 expression was analysed using monospeci®c antibodies developed by Roop et al. (1984) . Sections were incubated with the antibodies at a 1 : 500 dilution for K1, K14 and K6 and 1 : 800 for K13, followed by a secondary biotin-labeled anti-rabbit IgG and the avidin-peroxidase complex (ABC Vectastain, Elite, Vector Lab). Peroxidase reaction was detected using diaminobenzidine as a chromogen.
Indirect immuno¯uorescence staining for IGF-1
The expression and localization of IGF-1 was determined using immuno¯uorescence on sections of dorsal skins and skin tumors. The tissues were ®xed in formalin, embedded in paran and 4 mm sections were adhered to slides. After deparanization, the slides were microwaved twice for 5 min to enhance the staining of IGF-1. Sections were incubated with 10% non-immunized rabbit serum for 30 min to block the non-speci®c Fc-receptor in tissue and then washed three times with phosphate-buered saline pH 7.5, containing 1% bovine serum albumin (BSA/PBS). Sections were then incubated with either a 1 : 100 dilution of the primary sheep anti-human IGF-1 (Chemicon International, Inc, Temecula, CA) in BSA/PBS, or preimmune sheep serum as negative controls for 1 h. Following three washes with BSA/PBS, the sections were incubated with the secondary¯uorescence (FITC)-conjugated anity pure F(ab') 2 fragment rabbit anti-sheep PIgG (Jackson Immuno Research Lab, West Grove, PA) (1 : 200) for 40 min. The sections were then covered with Vestashield mounting solution (Vector Labs, Inc, Burlingame, CA) before the cover slips were attached. Immunospecificity of IGF-1 IgG was con®rmed by preabsorption with the antigen.
Tumor induction experiments
Tumor experiments were conducted using F 1 siblings born as a result of mating one male founder transgenic animal. Therefore, experiments were performed on mice from litters born over a 3 month period, with ages varying consistently between control and transgenic groups. Mice were shaved at least 2 days prior to initiation. For tumor initiation, 24 transgenic and 31 non-transgenic mice were treated topically with 25 nmol of DMBA in acetone on the shaved dorsal skin. After 4 weeks, each animal received subsequent topical treatments of 10 nmol of TPA in acetone twice-weekly for the duration of the experiment. Additionally, 18 transgenic and 19 nontransgenic age-matched N 1 F 1 littermates were given acetone only, at the time of initiation, and then received the identical promoter treatments. All four groups were examined for tumors once each week starting in the third week of TPA treatment, and records kept of tumor numbers on each mouse. At 12 weeks of promotion, one animal from each of the initiated groups of animals was sacri®ced and the tumors harvested for histological examination as described above.
Abbreviations IGF, insulin-like growth factor; HK1, human keratin 1; TPA, 12-O-tetradecanoylphorbol-13-acetate; RT ± PCR, reverse transcriptase-polymerase chain reaction.
